



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

Table of Contents and List of Tables

Copyright VENTURE PLANNING GROUP
This material is confidential for use by our clients only
and may not be reprinted or reproduced.

VPG Publications, Consulting, Clients ***www.VPGcorp.com***

VPG Market Research Reports ***www.VPGMarketResearch.com***

Partner Reports ***www.LeadingMarketResearch.com***

VENTURE PLANNING GROUP 1271 Avenue of the Americas, Suite 4300 New York, NY 10020
Phone + 1 212 564 2838 Fax + 1 212 564 8133 ***reports@vpgcorp.com***

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

- 1. Breast Cancer**
- 2. Lung Cancer**
- 3. Colon and Rectum Cancer**
- 4. Prostate Cancer**
- 5. Stomach Cancer**
- 6. Leukemia**
- 7. Lymphoma**
- 8. Oral Cancer**
- 9. Skin Cancer**
- 10. Uterine Cancer**
- 11. Ovarian Cancer**
- 12. Bladder Cancer**

B. Major Current And Emerging Cancer Diagnostic Tests

- 1. Introduction**
- 2. Tumor Marker Classification**
- 3. ACTH**
- 4. Alpha-Fetoprotein (AFP)**
- 5. Beta-2 Microglobulin**
- 6. CA 15-3/27.29**
- 7. CA 19-9**
- 8. CA-125**
- 9. Calcitonin**
- 10. Carcinoembryonic Antigen (CEA)**
- 11. Estrogen and Progesterone Receptors**
- 12. Ferritin**
- 13. Gastrin**
- 14. Human Chorionic Gonadotropin (HCG)**
- 15. Insulin**

Table of Contents (continued)

- 16. NSE**
- 17. Occult Blood**
- 18. PAP Smear/HPV**
- 19. Prostatic Acid Phosphatase (PAP)**
- 20. Prostate-Specific Antigen (PSA)**
- 21. Squamous Cell Carcinoma Antigen (SCC)**
- 22. T and B Lymphocytes**
- 23. TdT**
- 24. Thyroglobulin**
- 25. Tissue Polypeptide Antigen (TPA)**
- 26. Biochemical Tumor Markers**
 - ADA
 - B-Protein
 - PNP
 - 5'-Nucleotidase
- 27. Oncogenes**
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg
 - Sis
 - Src

Table of Contents (continued)

28. Polypeptide Growth Factors

- **Basic Fibroblast Growth Factor**
- **Beta-TGF**
- **Cachectin (TNT)**
- **Calmodulin**
- **ECFR**
- **Nerve Growth Factor (NGF)**
- **Epidermal Growth Factor (EGF)**
- **Ornithine Decarboxylase**
- **Transferrin**
- **Transforming Growth Factor-Alpha**

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- **Alpha-Interferon**
- **B Cell Growth Factors**
- **B Cell Growth Factor (BCGF)**
- **Gamma-Interferon**
- **Interleukin-1 (IL-1)**
- **Macrophage Activating Factor**

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- **N-Acetylglucosamine**
- **Actin**
- **Alpha-Actin**
- **Antineuronal Antibodies**
- **7B2**
- **B72.3**
- **Bax**
- **BCD-F9**
- **BLCA-4**
- **Blood Group Antigens A,B,H**
- **CA 50**
- **CA 72-4/TAG-72**
- **CA 195**
- **CA-242**
- **CA-549**
- **CAM 26**
- **CAR-3**

Table of Contents (continued)

- **Cathepsin-D**
- **Chromogranin A and B**
- **Cluster 1 Antigen**
- **Cluster-5/5A Antigen**
- **CTA**
- **CU18**
- **DR-70**
- **DU-PAN-2**
- **Endometrial Bleeding Associated Factor**
- **Endostatin**
- **Epithelial Membrane Antigen**
- **Feulgen Hydrolysis**
- **Fibronectin**
- **FSH**
- **(1->3)-L-fucosyltransferase**
- **Gastrin-Releasing Peptide (GRP)**
- **GDCFP-15**
- **Glucagon**
- **Glycoamines**
- **H23**
- **Her-2**
- **Human Carcinoma Antigen**
- **HPA**
- **HSP27**
- **Intermediate Filaments**
 - **Cytokeratins/CK18/Cyfra 21-1**
 - **Desmin**
 - **Gliofibrillary Acid Protein**
 - **Neurofilaments**
 - **Vimentin**
- **KA 93**
- **Kinases**
- **KP16D3**
- **LAI**
- **Leukocyte Common Antigen**
- **Lewis Antigens**
- **Lysophosphatidic Acid (LPA)**
- **Ma 695/Ma 552**
- **MABDF3**
- **MAG**
- **ME1**

Table of Contents (continued)

- **Minactivin**
- **MN/CA9**
- **MSA**
- **Mucin Cancer Antigen (MCA)**
- **Multiple Tumor Suppressor 1**
- **Myosin**
- **NEA-130**
- **NMP22**
- **OA-519**
- **Opiod Peptides**
- **P-glycoprotein**
- **Pancreatic Oncofetal Antigen (POA)**
- **Placental Lactogen**
- **PR92**
- **Proliferative Index, Ki-67**
- **Px**
- **RB Inactivation/Deletion**
- **Ret**
- **SCCL 175**
- **Selectin**
- **Sialic Acid**
- **Sialyl SSEA-1/SLX**
- **SN10**
- **Somatostatin**
- **TA-90**
- **TABA**
- **Tachykinin**
- **TAG 12**
- **TPS**
- **Troponin**
- **Tubulin**
- **VCAM**
- **VEGF**
- **Villen**

C. Instrumentation Review And Market Needs

1. **Abbott AxSYM**
2. **Abbott Architect c4000**
3. **Abbott Architect i2000 Series**
4. **Abbott Architect ci8200 System**

Table of Contents (continued)

5. *Beckman Coulter UniCel Series*
6. *Beckman Coulter Access*
7. *Binding Site ESP600*
8. *bioMerieux Mini Vidas*
9. *Carolina Chemistries BioLis 24i*
10. *DiaSorin Liaison*
11. *Horiba ABX Pentra 400*
12. *Inverness DS2*
13. *J&J Vitros ECi/ECiQ*
14. *J&J Vitros 3600*
15. *J&J Vitros 5600*
16. *Olympus AU5400*
17. *Olympus AU3000i*
18. *Olympus AU2700*
19. *Roche Modular Analytics*
20. *Roche Cobas Integra 400*
21. *Roche Cobas Integra 400 Plus*
22. *Roche Elecsys*
23. *Roche Cobas c311*
24. *Siemens ADVIA Centaur*
25. *Siemens Dimension*
26. *Siemens Dimension RxL Max*
27. *Siemens Dimension Vista 500*
28. *Siemens Immulite*
29. *Siemens Stratus*
30. *Tosoh AIA-Series*
31. *Vital Diagnostics ATAC 8000*
32. *Vital Diagnostics Envoy 500*
- D. *Current and Emerging Technologies*
 1. *Monoclonal and Polyclonal Antibodies*
 2. *Immunoassays*
 - a. *Technological Principle*
 - b. *Radioimmunoassay (RIA)*
 - c. *Enzyme Immunoassays (EIA)*
 - *Overview*
 - *ELISA*
 - *Immunofiltration*
 - *Particle-Membrane Capture Immunoassay*
 - *Enzyme Amplification*

Table of Contents (continued)

- d. *Fluorescent Immunoassays*
- e. *Luminescence*
 - *Chemiluminescence*
 - *Bioluminescence*
- f. *Latex Agglutination*
- g. *Immunoprecipitation*
- H. *Affinity Chromatographu*
- e. *Liposome Flow-Injection Immunoassay*
- 3. *Molecular Diagnostics*
 - a. *Technology Overview*
 - b. *Amplification Methods*
 - *PCR*
 - *DAP-PCR*
 - *Immuno-PCR*
 - *QC-PCR*
 - *CAR*
 - *DNA*
 - *HPA*
 - *LCR*
 - *NASBA*
 - *QBR*
 - *SDA*
 - *3 SR, and others*
- 4. *Chromosome Analysis*
 - a. *Chronic Myelogenous Leukemia (CML)*
 - b. *Acute Myeloid Leukemia (AML)*
 - c. *Acute Lymphoblastic Leukemia (ALL)*
 - d. *Malignant Lymphomas*
 - Lymphoid Malignancies*
 - e. *Chronic Lymphocytic Leukemia (CLL)*
 - f. *Solid Cancers*
 - g. *Chromosomal Translocation and Oncogenes*
- 5. *Artificial Intelligence*
- 6. *Flow Cytometry*
- 7. *Two Dimensional Gel Electrophoresis (2-DGE)*
- 8. *Biosensors*
- 9. *Competing/Complementing Technologies*
 - a. *CT*
 - b. *MRI*

Table of Contents (continued)

- c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- F. Personal Testing

Germany

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

- A. Internal Development
 - B. Collaborative Arrangements
 - C. University Contracts
 - D. Distribution Strategies
-
- 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition

Table of Contents (continued)

- D. Technological Edge and Limitations**
- E. Patent Protection**
- F. Regulatory Constraints**
- G. Decentralized Testing Market Challenges**

Competitive Profiles

- **Abbott**
- **AdnaGen/Alere**
- **Agilent Technologies**
- **Applied Gene Technologies**
- **Arca Biopharma**
- **Beckman Coulter/Danaher**
- **Becton Dickinson**
- **Biomedical Diagnostics**
- **bioMerieux**
- **Bio-Rad**
- **CellSearch**
- **Cepheid**
- **Correlogic Systems/Vermillion**
- **Decode Genetics**
- **Diadexus**
- **Diagnocure**
- **Diasorin**
- **Eiken Chemical**
- **Elitech Group**
- **Enterix**
- **Enzo Biochem**
- **Epigenomics**
- **Exact Sciences**
- **Fujirebio**
- **Guided Therapeutics**
- **Hologic/Gen-Probe**
- **Kreatech/Leica**
- **Kyowa Medex**
- **Mackay Life Sciences**
- **Myriad Genetics**

Table of Contents (continued)

- **OncoLab**
- **Otho-Clinical Diagnostics**
- **Panacea Pharmaceuticals**
- **Polartech**
- **Polymedco**
- **PreMD**
- **Qiagen**
- **Quest Diagnostics**
- **Radiant Pharmaceuticals**
- **Roche**
- **Scienion**
- **Sequenom**
- **Siemens Healthcare**
- **Takara Bio**
- **Targeted Diagnostics & Therapeutics**
- **Thermo Fisher**
- **Tosoh**
- **Veridex**
- **Wako Pure Chemicals**
- **Wallac/PE**
- **Zila/Alere**

Appendixes

- Appendix I: Major Universities and Research
Centers Developing Cancer Diagnostic
Technology and Applications**
- Appendix II: Assumed Currency Exchange Rates**

List of Tables

Tumor Marker Classification

***Major Companies Developing or Marketing
ACTH Tests***

***Major Companies Developing or Marketing
AFP Tests***

***Major Companies Developing or Marketing
Beta-2 Microglobulin Tests***

***Major Companies Developing or Marketing
CA 15-3/27.29 Tests***

***Major Companies Developing or Marketing
CA 19-9 Tests***

***Major Companies Developing or Marketing
CA 125 Tests***

***Major Companies Developing or Marketing
Calcitonin Tests***

***Major Companies Developing or Marketing
CEA Tests***

***Major Companies Developing or Marketing
Estrogen Receptor Tests***

***Major Companies Developing or Marketing
Progesterone Receptor Tests***

***Major Companies Developing or Marketing
Ferritin Tests***

***Major Companies Developing or Marketing
Gastrin Tests***

List of Tables (continued)

***Major Companies Developing or Marketing
HCG Tests***

***Major Companies Developing or Marketing
Insulin Tests***

***Major Companies Developing or Marketing
NSE Tests***

***Major Companies Developing or Marketing
Occult Blood Tests***

***Major Companies Developing or Marketing
PAP Smear/HPV Tests***

***Major Companies Developing or Marketing
PAP Tests***

***Major Companies Developing or Marketing
PSA Tests***

***Major Companies Developing or Marketing
Lymphocyte Subclassification Tests***

***Biochemical Markers Potential Applications
In Cancer Diagnosis***

***Oncogenes Potential Applications
In Cancer Diagnosis***

***Major Companies Developing or Marketing
Oncogene Tests***

***Growth Factors Potential Applications
In Cancer Diagnosis***

***Colony Stimulating Factors Potential
Applications in Cancer Diagnosis***

***Lymphokines Potential Applications
In Cancer Diagnosis***

List of Tables (continued)

***Immunohistochemical Stains Potential
Applications in Cancer Diagnosis***

***Executive Summary Table: Germany, Hospital
Cancer Diagnostic Test Volume and Sales Forecast***

***Germany, Estimated Cancer Death Rates
Per 100,000 Population***

***Germany, Hospital Laboratories Performing Cancer
Diagnostic Tests***

***Germany, Hospital Laboratories Performing
Cancer Diagnostic Tests by Bed Size***

***Germany, Hospital Laboratories, Major
Cancer Diagnostic Test Volume Forecast
by Test***

***Germany, Total Cancer Diagnostics Sales
By Major Supplier***

***Germany, AFP Testing Market Diagnostics
Sales by Major Supplier***

***Germany CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier***

***Germany CA 19-9 Testing Market Diagnostics
Sales by Major Supplier***

***Germany, CA 125 Testing Market Diagnostics
Sales by Major Supplier***

***Germany, CEA Testing Market Diagnostics
Sales by Major Supplier***

***Germany, PSA Testing Market Diagnostics
Sales by Major Supplier***